Nervous system autoantibodies and vitamin D receptor gene polymorphisms in hemodialysis patients

Hemodialysis International

Volumn 17, Issue 1, 2013, Pages 3-11

  Mason, Darius L ^a   Assimon, Magdalene M ^a   Bishop, Jeffrey R ^b   El Fawal, Hassan A N ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Autoantibodies; Ergocalciferol; Nervous system; Polymorphism; VDR; Vitamin D

Indexed keywords

ALBUMIN; AUTOANTIBODY; CALCIUM; ERGOCALCIFEROL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN ANTIBODY; HEMOGLOBIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN ANTIBODY; NEUROFILAMENT PROTEIN; PARATHYROID HORMONE; PROTEIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HEMODIALYSIS PATIENT; HUMAN; IMMUNOASSAY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NERVOUS SYSTEM; NEUROFILAMENT; NEUROPROTECTION; PATIENT MONITORING; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN D DEFICIENCY;

AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NERVOUS SYSTEM; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RENAL DIALYSIS;

EID: 84872656566     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00727.x     Document Type: Article

References (42)

1. Madero M, Sarnak MJ. Does hemodialysis hurt the brain? Semin Dial. 2011; 24:266-268.
2. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: An occult burden. Adv Chronic Kidney Dis. 2008; 15:123-132.
3. Griva K, Stygall J, Hankins M, Davenport A, Harrison M, Newman SP. Cognitive impairment and 7-year mortality in dialysis patients. Am J Kidney Dis. 2010; 56:693-703.
4. Murray AM, Tupper DE, Knopman DS, etal. Cognitive impairment in hemodialysis patients is common. Neurology. 2006; 67:216-223.
5. Buell JS, Dawson-Hughes B, Scott TM, etal. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010; 74:18-26.
6. Giang LM, Weiner DE, Agganis BT, etal. Cognitive function and dialysis adequacy: No clear relationship. Am J Nephrol. 2010; 33:33-38.
7. Kurella Tamura M, Larive B, Unruh ML, etal. Prevalence and correlates of cognitive impairment in hemodialysis patients: The frequent hemodialysis network trials. Clin J Am Soc Nephrol. 2010; 5:1429-1438.
8. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis. 1999; 33:1122-1130.
9. Marsh JT, Brown WS, Wolcott D, etal. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int. 1991; 39:155-163.
10. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001; 21:98-108.
11. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005; 29:21-30.
12. Slinin Y, Paudel ML, Taylor BC, etal. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology. 2010; 74:33-41.
13. Clemens TL, Garrett KP, Zhou XY, Pike JW, Haussler MR, Dempster DW. Immunocytochemical localization of the 1, 25-dihydroxyvitamin D3 receptor in target cells. Endocrinology. 1988; 122:1224-1230.
14. Neveu I, Naveilhan P, Jehan F, etal. 1, 25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res. 1994; 24:70-76.
15. Zehnder D, Bland R, Williams MC, etal. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001; 86:888-894.
16. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M. 1, 25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport. 1994; 6:124-126.
17. Kurella Tamura M, Yaffe K. Dementia and cognitive impairment in ESRD: Diagnostic and therapeutic strategies. Kidney Int. 2011; 79:14-22.
18. Masoumi A, Goldenson B, Ghirmai S, etal. 1alpha, 25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009; 17:703-717.
19. Miller JW. Vitamin D and cognitive function in older adults: Are we concerned about vitamin d-mentia? Neurology. 2010; 74:13-15.
20. Annweiler C, Schott AM, Rolland Y, Blain H, Herrmann FR, Beauchet O. Dietary intake of vitamin D and cognition in older women: A large population-based study. Neurology. 2010; 75:1810-1816.
21. Wilkins CH, Birge SJ, Sheline YI, Morris JC. Vitamin D deficiency is associated with worse cognitive performance and lower bone density in older African Americans. J Natl Med Assoc. 2009; 101:349-354.
22. Yaffe K, Ackerson L, Kurella Tamura M, etal. Chronic kidney disease and cognitive function in older adults: Findings from the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc. 2010; 58:338-345.
23. Llewellyn DJ, Lang IA, Langa KM, etal. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010; 170:1135-1141.
24. Kuningas M, Mooijaart SP, Jolles J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging. 2009; 30:466-473.
25. Gezen-Ak D, Dursun E, Ertan T, etal. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med. 2007; 212:275-282.
26. Kim JS, Kim YI, Song C, etal. Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci. 2005; 20:495-498.
27. El-Fawal HA, Waterman SJ, De Feo A, Shamy MY. Neuroimmunotoxicology: Humoral assessment of neurotoxicity and autoimmune mechanisms. Environ Health Perspect. 1999; 107(Suppl 5):767-775.
28. El-Fawal HA, O'Callaghan JP. Autoantibodies to neurotypic and gliotypic proteins as biomarkers of neurotoxicity: Assessment of trimethyltin (TMT). Neurotoxicology. 2008; 29:109-115.
29. Gong G, Stern HS, Cheng SC, etal. The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos Int. 1999; 9:55-64.
30. van Meurs JB, Schuit SC, Weel AE, etal. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet. 2003; 12:1745-1754.
31. Wennberg P, Nordstrom P, Lorentzon R, Lerner U, Lorentzon M. TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents. Eur J Endocrinol. 2002; 146:629-634.
32. El-Fawal HA, McCain WC. Antibodies to neural proteins in organophosphorus-induced delayed neuropathy (OPIDN) and its amelioration. Neurotoxicol Teratol. 2008; 30:161-166.
33. Berger T, Rubner P, Schautzer F, etal. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003; 349:139-145.
34. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf. 2005; 4:433-442.
35. Zhang Y, Popovich P. Roles of autoantibodies in central nervous system injury. Discov Med. 2011; 11:395-402.
36. Terryberry JW, Thor G, Peter JB. Autoantibodies in neurodegenerative diseases: Antigen-specific frequencies and intrathecal analysis. Neurobiol Aging. 1998; 19:205-216.
37. El-Fawal HAN. Neurotoxicology. In: Jo N, ed. Encyclopedia of Environmental Health. Vol. 4: Burlington: Elsevier. 2011; 87-106.
38. Kamchatnov PR, Chugunov AV, Ruliaeva N, Dugin SF, Buriachkovskaia LI, Umarova K. Autoantibodies to glial fibrillary acid protein in patients with different forms of cerebral vascular pathology. Zh Nevrol Psikhiatr Im S S Korsakova. 2008; 108:58-61.
39. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis. 2007; 4:185-194.
40. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009; 132(Pt 5):1146-1160.
41. Annweiler C, Allali G, Allain P, etal. Vitamin D and cognitive performance in adults: A systematic review. Eur J Neurol. 2009; 16:1083-1089.
42. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: Preventing "D"ecline? Mol Aspects Med. 2008; 29:415-422.